Lowest Price Guaranteed From USD 3,999
Published
January 2019
Pages
230
View Count
14585
Example Insights
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
Report Description
In my opinion, the global market for drug delivery technologies is still in its infancy and I expect a significant growth once technologies under evaluation are clinically validated and begin to generate revenues. Until this takes place, the market is likely to be driven by technology access fees, and upfront and milestone payments.
-- CEO, a California-based mid-sized technology developer
The revenues generated from the licensing of novel technologies for delivery of proteins, antibodies and nucleic acids are likely to increase significantly from $226 million to $2,237 million by 2030. Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. In 2018, over 15 biological license applications (BLA) received approval. Previously, in 2017, 12 new biologics were approved by the US FDA, which included antibodies (9), antibody-drug conjugates (1), and enzymes (2). Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing and administration. Specifically, the challenges associated with the delivery of such drugs can be attributed to their large molecular weight, short half-lives, and instability in the gastrointestinal (GI) tract and intestinal lumen. Owing to their susceptibility to enzymatic degradation, the parenteral route of administration is considered to be the most acceptable mode of delivery, enabling such drugs to directly enter systemic circulation. However, parenteral administration often requires patients to visit healthcare centers / clinics for dosing. As a result, non-adherence to prescribed therapeutic regimens is rampant among end-users.
Despite these challenges, the demand for biologics is high because of their favorable safety profiles, greater systemic compatibility and fewer side effects. As a result, medical researchers and therapy developers are actively attempting to identify and exploit alternative delivery strategies for such products; examples include aerosol generation systems, lipid nanoparticles, DNA-based delivery technologies, and brain shuttles (designed to facilitate increased drug penetration across the elusive blood-brain barrier). Currently, several biopharmaceutical companies have undertaken initiatives to develop cell-specific drug delivery technologies and have superior formulation technologies, imparting improved release properties to drugs being delivered. Consequently, pharmaceutical developers are likely to witness a rise in available options for the delivery of their respective products in the foreseen future.
The “Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030” report features an extensive study of the current market landscape and the likely future adoption of such technologies, over the next twelve years. The study features an in-depth analysis, highlighting:
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the administration of proteins, antibodies and nucleic acids. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2018-2030. The report features likely distribution of the current and forecasted opportunity across the [A] type of therapeutic area (oncology and non-oncology), [B] route of administration (parenteral and non-parenteral), [C] key contributing technologies and [D] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for novel technologies for delivery of proteins, antibodies and nucleic acids, in the short-mid term and long term.
Chapter 3provides a general introduction on the importance of effective drug delivery systems for biotherapeutics. It highlights the different types of biologics and the various route of administration used for the delivery of such products. It includes a discussion on the growing demand for biotherapeutics. The chapter lays emphasis on the key challenges faced during drug delivery and, subsequently, provides an overview of advanced drug delivery technologies that are already available in the market or under development.
Chapter 4presents a list of novel technologies designed for the delivery of biotherapeutics. It includes a detailed analysis of the aforementioned technologies based on the type of biologics, impact on drug properties and patient compliance, route of administration and the developer details (such has company size and location of company headquarters). In addition, the chapter features a list of companies developing formulation technologies.
Chapter 5presents a competitiveness analysis of all technologies based on supplier power and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6provides detailed profiles of the technologies which emerged to be relatively more superior than the others in the product competitiveness analysis. Each profile presents a brief overview of the company, technology description, intellectual property portfolio and recent developments.
Chapter 7provides detailed profiles of some of the leading stakeholders in this field. Each profile includes a brief overview of the company, its financial performance (if available), information on its product portfolio, recent developments and a comprehensive future outlook.
Chapter 8provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to novel technologies for administration of biologics. For this analysis, we looked at the patents that have been published by various players, till November 2018. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), publication year, patent issuing authorities / patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging focus areas and the leading industry / academic players. The chapter also includes a patent benchmarking analysis and comprehensive valuation analysis.
Chapter 9features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, licensing agreements, manufacturing agreements, mergers / acquisitions and R&D agreements) and the most common forms of deals / agreements that have been established between 2010 to 2018.Chapter 10features a comprehensive market forecast analysis, highlighting the likely growth of novel technologies for delivery of biologics market till the year 2030. We have provided inputs on the likely distribution of the opportunity by type of therapeutic area (oncological, neurodegenerative, metabolic, infectious, ophthalmology and others), route of administration (parenteral, oral, inhalation and others), different regions (North America, Europe, Asia Pacific and rest of the world) and key contributing technologies.
Chapter 11features a discussion onupcoming technologies / trends that are likely to present future growth opportunities in the field of biotherapeutic delivery. It highlights the key drivers of growth and projected adoption trends of technical innovations that are likely to have a notable influence on the industry’s evolution over the coming decade.
Chapter 12is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Mathias Schmidt (Chief Executive Officer, ArmaGen), Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International), Donovan Yeates (Chief Executive Officer and Chief Scientific Officer, Chairman and Founder, KAER Biotherapeutics).
Chapter 13is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Biopharmaceuticals
3.2. Demand for Biopharmaceuticals
3.3. Types of Biopharmaceuticals
3.3.1. Proteins and Peptides
3.3.2. Antibodies
3.3.3. Nucleic Acids
3.4. Common Routes of Administration for Biopharmaceuticals
3.4.1. Parenteral Delivery
3.4.1.1. Intravenous Route
3.4.1.2. Intramuscular Route
3.4.1.3. Subcutaneous Route
3.4.2. Non-Parenteral Delivery
3.4.2.1. Buccal / Sublingual Route
3.4.2.2. Intranasal Route
3.4.2.3. Inhalation / Pulmonary Route
3.4.2.4. Ocular Route
3.4.2.5. Oral Route
3.4.2.6. Rectal Route
3.4.2.7. Transdermal Route
3.5. Key Challenges Associated with Drug Delivery
3.6. Advanced Approaches for Delivery of Biotherapeutics
3.6.1. Muco-Adhesive Polymeric Systems
3.6.2. Nanoparticle-based Delivery Systems
3.6.3. Other Drug Delivery Technologies
3.7. Demand for Novel Drug Delivery Technologies
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Overall Market Landscape
4.2.1. Analysis by Size of Developer Company
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Biologics Delivered
4.2.5. Analysis by Impact of Technology on Drug Properties / Patient Compliance
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Geographical Location of Developer Company
4.3. Grid Analysis: Distribution by Type of Biologics, Route of Administration and Drug Delivery Parameters
4.4. List of Drug Formulation Technologies
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Technologies of Companies Based in North America
5.2.2. Technologies of Companies Based in Europe
5.2.3. Technologies of Companies Based in Asia-Pacific
6. TECHNOLOGY PROFILES
6.1. Chapter Overview
6.1.1. HEPtune® Technology
6.1.1.1. Developer Overview
6.1.1.2. Technology Overview
6.1.1.3. Recent Collaborations
6.2. Intravail® Technology
6.2.1. Developer Overview
6.2.2. Technology Overview
6.2.3. Recent Collaborations
6.3. RapidMist™
6.3.1. Developer Overview
6.3.2. Technology Overview
6.3.3. Recent Collaborations
6.4. TheraKine Technology
6.4.1. Developer Overview
6.4.2. Technology Overview
6.4.3. Recent Collaborations
6.5. Arestat™ Technology
6.5.1. Developer Overview
6.5.2. Technology Overview
6.5.3. Recent Collaborations
6.6. DelSiTech™ Silica Matrix
6.6.1. Developer Overview
6.6.2. Technology Overview
6.6.3. Recent Collaborations
6.7. ImSus® Technology
6.7.1. Developer Overview
6.7.2. Technology Overview
6.7.3. Recent Collaborations
6.8. PLEX™ Technology
6.8.1. Developer Overview
6.8.2. Technology Overview
6.8.3. Recent Collaborations
6.9. ENHANZE® Technology
6.9.1. Developer Overview
6.9.2. Technology Overview
6.9.3. Recent Collaborations
7. COMPANY PROFILES: DRUG DELIVERY PLATFORM PROVIDERS
7.1. Chapter Overview
7.2. Aphios
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Technology Overview
7.2.4. Recent Developments
7.2.5. Future Outlook
7.3. Arbutus Biopharma
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Technology Overview
7.3.4. Recent Developments
7.3.5. Future Outlook
7.4. Camurus
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Technology Overview
7.4.4. Recent Developments
7.4.5. Future Outlook
7.5. ConjuChem
7.5.1. Company Overview
7.5.2. Technology Overview
7.5.3. Future Outlook
7.6. InnoCore Pharmaceuticals
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Technology Overview
7.6.4. Recent Developments
7.6.5. Future Outlook
7.7. LATITUDE Pharmaceuticals
7.7.1. Company Overview
7.7.2. Technology Overview
7.7.3. Recent Developments
7.7.4. Future Outlook
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority / Patent Offices Involved
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Focus Areas
8.3.5. Leading Players Based on Number of Patents
8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Patent Valuation Analysis
9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Analysis by Type of Technology
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Regional Analysis
9.3.6.1. Intercontinental and Intracontinental Agreements
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
10.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030
10.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030
10.5.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030
10.5.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030
10.5.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030
10.6. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030
10.6.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030
10.6.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030
10.6.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030
10.6.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030
10.6.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030
10.6.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030
10.7. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
10.8. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030
10.8.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Parenteral Route, 2019 and 2030
10.8.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Oral Route, 2019 and 2030
10.8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030
10.8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030
10.9. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030
11. FUTURE GROWTH OPPORTUNITIES
11.1. Chapter Overview
11.2. The Industry Has Recently Witnessed A Shift from Conventional Nanoparticle-Based Technologies to DNA-Based Solutions
11.3. Despite Extensive Research Efforts in this Domain, There is Still A Substantial Unmet Need Related To Drug Delivery Technologies For Neurodegenerative Disorders
11.4. The Oral Route of Delivery, Owing to its Capability to Ensure Therapy Adherence, Has Garnered Significant Attention in this Market
11.5. Impending Patent Expirations Have Prompted Many Players to Adopt Various Life Cycle Management Strategies to Sustain Revenue Generation Potential
11.6. The Larger Market Share is Currently with the Developed Regions, while Contributions from Technology Providers in the Asia Pacific are Expected to Increase in the Foreseen Future
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. ArmaGen
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
12.4. KAER Biotherapeutics
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer and Chief Scientific Officer, Chairman and Founder
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Types of Biologics
Figure 3.2 Biologics and Small Molecules: Comparison of Key Characteristics
Figure 3.3 Routes of Administration for Protein Delivery
Figure 3.4 Drug Transport through the Intestinal Epithelium
Figure 3.5 DNA- based Delivery Platform
Figure 4.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Size of Developer Company
Figure 4.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Year of Establishment
Figure 4.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Technology
Figure 4.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Biologics Delivered
Figure 4.5 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance
Figure 4.6 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Administration
Figure 4.7 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Geographical Location of Developer
Figure 4.8 Grid Analysis: Distribution by Types of Biologics Delivered, Route of Administration and Impact of Technology on Drug Properties / Patient Compliance
Figure 5.1 Product Competitiveness Analysis: Technologies of Companies Based in North America (Peer Group I)
Figure 5.2 Product Competitiveness Analysis: Technologies of Companies Based in North America (Peer Group II)
Figure 5.3 Product Competitiveness Analysis: Technologies of Companies Based in Europe
Figure 5.4 Product Competitiveness Analysis: Technologies of Companies Based in Asia-Pacific
Figure 6.1 Arecor: Advantages of Arestat™ Technology
Figure 6.2 DelSiTech: Advantages of Silica-Based Technologies
Figure 6.3 ALRISE Biosystems: Advantages of ImSus® Technology
Figure 7.1 Arbutus Biopharma: Annual Revenues, 2012- 2018 (USD Million)
Figure 7.2 Camurus: Annual Revenues, 2013- 2018 (SEK Million)
Figure 7.3 Camurus: Process of Delivery of FluidCrystal® Injection
Figure 7.4 Common Formulation Challenges Addressed by Nano-E™
Figure 7.5 Common Formulation Challenges Addressed by PG™ Depot Platform
Figure 8.1 Patent Portfolio: Distribution by Type of Patent
Figure 8.2 Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Figure 8.3 Patent Portfolio: Distribution by Patent Issuing Authority / Patent Offices Involved
Figure 8.4 Patent Portfolio: Distribution by CPC Classification Symbols
Figure 8.5 Patent Portfolio: Word Cloud of Emerging Areas
Figure 8.6 Patent Portfolio: Distribution by Leading Players
Figure 8.7 Patent Portfolio: Benchmarking by Patent Characteristics (CPC Classifications)
Figure 8.8 Patent Portfolio: Benchmarking by International Patents
Figure 8.9 Patent Portfolio: Distribution by Patent Age (January 2010 - November 2018)
Figure 8.10 Patent Portfolio: Valuation Analysis
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2010-2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Analysis by Number and Type of Partnerships, 2010-2014 and 2015-2018
Figure 9.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.5 Partnerships and Collaborations: Most Popular Technologies
Figure 9.6 Partnerships and Collaborations: Most Active Players
Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
Figure 10.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Upfront Payments (Units, USD Million)
Figure 10.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Milestone Payments (Units, USD Million)
Figure 10.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030 (USD Billion)
Figure 10.5 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030 (USD Billion)
Figure 10.6 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030 (USD Billion)
Figure 10.7 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030 (USD Billion)
Figure 10.8 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030 (USD Billion)
Figure 10.9 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030 (USD Billion)
Figure 10.10 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030 (USD Billion)
Figure 10.11 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030 (USD Billion)
Figure 10.12 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030 (USD Billion)
Figure 10.13 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030 (USD Billion)
Figure 10.14 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030 (USD Billion)
Figure 10.15 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030 (USD Billion)
Figure 10.16 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
Figure 10.17 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030 (USD Billion)
Figure 10.18 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Parenteral Route, 2019 and 2030 (USD Billion)
Figure 10.19 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Oral Route, 2019 and 2030 (USD Billion)
Figure 10.20 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030 (USD Billion)
Figure 10.21 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030 (USD Billion)
Figure 10.22 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030 (USD Billion)
Table 3.1 Top Selling Biologics Table 3.2 List of Approved Monoclonal Antibodies
Table 4.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: List of Companies
Table 4.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Biologics
Table 4.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance
Table 4.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Administration
Table 4.5 List of Formulation Technologies
Table 6.1 List of Technologies Profiled
Table 6.2 Arecor: Product Portfolio
Table 6.3 DelSitech: Product Portfolio
Table 6.4 PolyPid: Product Portfolio
Table 7.1 Detailed Profiles: Key Technology Providers
Table 7.4 Camurus: Product Portfolio
Table 7.6 ConjuChem: Product Portfolio
Table 8.1 Patent Portfolio: Most Popular CPC Symbols
Table 8.2 Patent Portfolio: List of Top CPC Classifications
Table 8.3 Patent Portfolio: Categorization based on Weighted Valuation Scores
Table 9.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Partnerships and Collaborations, 2010-2018
Table 13.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Employee Size of Developer Company
Table 13.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Year of Establishment
Table 13.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Technology
Table 13.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Type of Biologics Delivered
Table 13.5 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance
Table 13.6 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Route of Administration
Table 13.7 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Geographical Location of Developer
Table 13.8 Arbutus Biopharma: Annual Revenues, 2012- 2018 (USD Million)
Table 13.9 Camurus: Annual Revenues, 2013- 2018 (SEK Million)
Table 13.10 Patent Portfolio: Distribution by Type of Patent
Table 13.11 Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Table 13.12 Patent Portfolio: Distribution by Issuing Authorities / Patent Offices Involved
Table 13.13 Patent Portfolio: Distribution by Leading Players
Table 13.14 Patent Portfolio: Benchmarking by International Patents
Table 13.15 Patent Portfolio: Distribution by Patents Age (January 2010-November 2018)
Table 13.16 Patent Portfolio: Valuation Analysis
Table 13.17 Partnerships and Collaborations: Cumulative Trend by Year, 2010-2018
Table 13.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.19 Partnership and Collaboration: Analysis by Number and Type of Partnerships, 2010-2014 and 2015-2018
Table 13.20 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.21 Partnerships and Collaborations: Most Popular Technologies
Table 13.22 Partnerships and Collaborations: Most Active Players
Table 13.23 Partnerships and Collaborations: Regional Distribution
Table 13.24 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 13.25 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
Table 13.26 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Upfront Payments (Units, USD Million)
Table 13.27 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Milestone Payments (Units, USD Million)
Table 13.28 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, Conservative, Base and Optimistic Scenario, 2019-2030 (USD Million)
Table 13.29 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030 (USD Billion)
Table 13.30 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030 (USD Billion)
Table 13.31 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030 (USD Billion)
Table 13.32 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030 (USD Billion)
Table 13.33 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030 (USD Billion)
Table 13.34 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030 (USD Billion)
Table 13.35 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030 (USD Billion)
Table 13.36 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030 (USD Billion)
Table 13.37 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030 (USD Billion)
Table 13.38 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030 (USD Billion)
Table 13.39 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030 (USD Billion)
Table 13.40 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
Table 13.41 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030 (USD Billion)
Table 13.42 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Parenteral Route, 2019 and 2030 (USD Billion)
Table 13.43 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Oral Route, 2019 and 2030 (USD Billion)
Table 13.44 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030 (USD Billion)
Table 13.45 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030 (USD Billion)
Table 13.46 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030 (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES